Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHACRYNIC ACID vs FUROSCIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Treatment of edema associated with congestive heart failure, cirrhosis, and renal disease,Treatment of ascites,Treatment of hypertension (off-label),Adjunctive therapy in acute pulmonary edema (off-label)
Treatment of edema associated with congestive heart failure,Treatment of edema associated with cirrhosis of the liver,Treatment of edema associated with renal disease including nephrotic syndrome
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (Cr Cl <30 m L/min) and 9-19 hours in anuria
Primarily metabolized by conjugation with glutathione; also undergoes hepatic metabolism via CYP450 enzymes (minor).
Furosemide is primarily metabolized by glucuronidation via UGT1A1, UGT1A9, and UGT2B7; to a lesser extent by cytochrome P450 enzymes.
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Approximately 90-98% bound to plasma proteins, primarily albumin.
91-99%, primarily to albumin
Volume of distribution is approximately 0.1-0.2 L/kg, indicating limited extravascular distribution.
0.1-0.2 L/kg; higher in neonates (0.2-0.4 L/kg); restricted to extracellular fluid in adults
Oral bioavailability is approximately 100%.
Subcutaneous: 99% compared to IV; oral: 60-70% (variable due to first-pass metabolism)
e GFR 30-59 m L/min: no adjustment; e GFR <30 m L/min: avoid use due to risk of ototoxicity and decreased efficacy.
e GFR 15-29 m L/min/1.73m2: 40 mg subcutaneously once daily. e GFR <15 m L/min: not recommended. e GFR ≥30: no adjustment needed.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A or B: no adjustment. Child-Pugh C: use with caution; reduce dose to 40 mg subcutaneously once daily. No specific pharmacokinetic data in severe impairment.
Oral: 1 mg/kg/dose once daily; may increase by 1 mg/kg/dose at intervals of 2-3 days up to 3 mg/kg/day. IV: 1 mg/kg/dose slow IV; maximum 50 mg/dose.
Safety and efficacy not established in pediatric patients (<18 years). No approved dosing available.
Initiate at lower doses (25 mg orally once daily) due to increased risk of electrolyte disturbances and renal impairment; monitor closely.
Start at 40 mg subcutaneously once daily. Monitor renal function and electrolyte levels closely. Consider lower doses due to age-related decreased renal function.
This drug is a potent diuretic which, if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose adjustment are required.
Furosemide can cause profound diuresis with water and electrolyte depletion, leading to serious adverse events such as circulatory collapse and thromboembolic complications. Careful medical supervision is required.
Risk of excessive diuresis leading to dehydration, electrolyte imbalance, and hypovolemia,May cause ototoxicity, especially with rapid IV administration or in patients with renal impairment,Can worsen azotemia or precipitate hepatic encephalopathy in cirrhotic patients,Monitor serum electrolytes, CO2, BUN, and creatinine regularly,Use with caution in patients with diabetes mellitus (may increase blood glucose),May cause hyperuricemia and gout
Monitor for electrolyte disturbances (e.g., hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia),May cause ototoxicity, especially with rapid injection or high doses,Risk of renal impairment; monitor renal function,Can exacerbate systemic lupus erythematosus,Avoid in patients with known sulfonamide allergy
Anuria,Hypersensitivity to ethacrynic acid or any component of the formulation,Severe electrolyte depletion (hypokalemia, hyponatremia) until corrected,Concurrent use with other ototoxic drugs (e.g., aminoglycosides) may increase risk
Anuria,Severe hypokalemia,Severe hyponatremia,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or pre-coma
Avoid licorice, which can worsen hypokalemia. Limit salt intake as directed. No specific food interactions; maintain a balanced diet.
Avoid foods high in sodium (e.g., processed meats, canned soups) to reduce fluid retention. No significant food-drug interactions. May increase potassium and magnesium loss; ensure adequate intake of potassium-rich foods (e.g., bananas, oranges) but monitor levels closely.
First trimester: Limited human data; animal studies show no teratogenicity but fetal toxicity at high doses. Second trimester: Theoretical risk of electrolyte imbalances affecting fetal development. Third trimester: Risk of premature ductus arteriosus closure due to prostaglandin inhibition (theoretical), neonatal ototoxicity, and thrombocytopenia.
Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause maternal hypovolemia, reduced placental perfusion, and fetal oligohydramnios; avoid if possible. Not associated with major congenital malformations.
Safety not established. Drug excreted in breast milk; M/P ratio unknown. Avoid breastfeeding or use with caution due to potential for ototoxicity and electrolyte disturbances in the infant.
Furosemide is excreted into human breast milk in low amounts (M/P ratio approximately 0.2-0.5). Peak milk concentration ~0.4-0.6 µg/m L after 40 mg oral dose. Limited data suggest no adverse effects in breastfed infants. Use with caution, especially in neonates due to risk of diuresis and electrolyte imbalance.
No standard dose adjustment; use lowest effective dose. Monitor for hypokalemia and volume depletion, which may be more pronounced in pregnancy. Consider adjusting dose based on maternal weight and renal function.
Furosemide pharmacokinetics may be altered in pregnancy due to increased volume of distribution and renal clearance. Lower doses may achieve desired diuresis; start at low end of dosing range (20-40 mg/day oral) and titrate based on clinical response and monitoring. Avoid high doses and prolonged use due to risk of hypovolemia and placental hypoperfusion.
Ethacrynic acid is a loop diuretic used for patients with sulfonamide allergy, as it is not a sulfonamide derivative. Monitor for ototoxicity, especially when given with aminoglycosides or in renal impairment. Rapid diuresis may cause hypokalemia, hypomagnesemia, and metabolic alkalosis. Use cautiously in hepatic cirrhosis to avoid electrolyte-induced coma.
FUROSCIX (furosemide) is a subcutaneous loop diuretic for heart failure congestion. Onset of diuresis within 30 minutes; peak effect at 1-2 hours. Monitor for hypokalemia, hypomagnesemia, and ototoxicity. Use with caution in sulfonamide allergy. Avoid concurrent use with NSAIDs as they reduce diuretic efficacy.
Take exactly as prescribed, usually once or twice daily.,Expect increased urination; take in the morning to avoid nighttime trips.,Weigh yourself daily and report rapid weight gain or loss.,Avoid alcohol and medications that may cause dizziness.,This drug may cause hearing loss or ringing in the ears; report immediately.,Do not take with aspirin or other NSAIDs without doctor approval.,Inform your doctor if you have gout, diabetes, or kidney disease.,Stay adequately hydrated but avoid excessive fluid intake.
Inject subcutaneously into the abdomen; rotate sites.,Take in the morning to avoid nocturia.,Monitor daily weight and report >2 lb/day gain.,Report hearing changes, ringing in ears, or dizziness.,Avoid excessive salt intake; limit alcohol.,Do not use with NSAIDs or lithium without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHACRYNIC ACID vs FUROSCIX, answered by our medical review team.
ETHACRYNIC ACID is a Loop Diuretic that works by Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.. FUROSCIX is a Loop Diuretic that works by Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHACRYNIC ACID and FUROSCIX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHACRYNIC ACID is: 50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.. The standard adult dose of FUROSCIX is: 80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHACRYNIC ACID and FUROSCIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHACRYNIC ACID is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity but fetal toxicity at high doses. Second trimester: Theoretical risk of electrolyte imbalances affecting . FUROSCIX is classified as Category C. Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.